{"entity":{"id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AK109+AK104 in advanced solid tumours, run by Akeso, now recruiting.","summary":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05142423 by Akeso, with 198 participants planned, started 2021-11-03 and due to reach its primary completion in 2027-04. Interventions recorded: AK109+AK104.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05142423","url":"https://clinicaltrials.gov/study/NCT05142423"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05142423","phase":"1/2","setting":"An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors","sponsor":"Akeso","enrolled":198,"outcomes":[]},"route":"/trials/nct05142423/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}